

Meeting Minutes: Drug Formulary Committee - DRAFT

Date and Time: November 16, 2022; 5:15 – 9 p.m.
Minutes prepared by: Naana Osei-Boateng and Dave Hoang
Location: Virtual Meeting via Zoom and In-Person Meeting in Room 2370, Elmer Andersen Building, St. Paul, MN

Attendance

- Members in attendance: Stuart Williams, JD.; Kelly Ruby, PharmD.; Monica Brands, RPh.; Kathryn Lombardo, MD.; Margaret Artz, RPh., PhD.; Kathryn Montag-Shafer, PharmD.; Ronda Chakolis, PharmD.; Tim Cernohous, PharmD; Kyle Lehenbauer, MD.; James Phillips, MD; Mary Mescher Benbenek, APRN, PhD.
- Members absent: Tsewang Ngodup, MD.; Michael Sprehe, MD.
- DHS staff present: Dave Hoang, PharmD., MBA; Chad Hope, PharmD.
- Others in attendance: Katie Counts, PharmD.; Umang Patel, PharmD.; Naana Osei-Boateng, PharmD.

Report of the Chair

- Stuart Williams presided over the meeting.
- Minutes from the August 2022 meeting were reviewed and accepted as presented.

DHS Housekeeping

- DHS and the DFC discussed the optimal meeting time and duration for the DFC.
- DHS encouraged all stakeholders and interested parties to submit their comments to the DFC email address.
- DHS will provide an update at the next meeting of the DFC.

Old Business – None

New Business

- Data collection process for the MN Cost of Dispensing Survey is in progress. All pharmacies are required to respond.
- Active recruitment for practicing physicians to join the DFC is ongoing.

CONSENT AGENDA ITEMS:

- The committee discussed and recommended by unanimous vote that all classes in the Consent Agenda Items be passed as presented:
 - HEPATITIS B AGENTS
 - LEUKOTRIENE MODIFIERS
 - LIPOTROPICS, STATINS
 - NEUROPATHIC PAIN
 - OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
 - PANCREATIC ENZYMES
 - PHOSPHATE BINDERS
 - PLATELET AGGREGATION INHIBITORS
 - PROGESTINS FOR CACHEXIA
 - PROTON PUMP INHIBITORS
 - SICKLE CELL ANEMIA TREATMENTS
 - DIABETES METERS, CONTINUOUS
 - TRANSMITTERS AND SENSORS

DISCUSSION ITEMS:

- The committee discussed the Cytokine and CAM Antagonists therapeutic class and recommended the following to the department by a unanimous vote:
 - HUMIRA PEN KIT (INJECTION) and ENBREL CARTRIDGE (SUBCUTANE.) – correct clerical errors
 - XELJANZ (ORAL) to be moved to the PDL as PREFERRED
 - ENSPRYNG (SUBCUTANEOUS), INFlixIMAB (INJECTION) and UPLIZNA (INTRAVEN.) to be added to the PDL as NONPREFERRED
- The committee discussed the Hepatitis C Agents therapeutic class and recommended by unanimous vote that that the class be passed with no changes.
- The committee discussed Hypoglycemics, Insulin and Related Agents therapeutic class and recommended the following to the department by a unanimous vote:
 - INSULIN DEGLUDEC VIAL (SUBCUTANE.), INSULIN DEGLUDEC PEN (U-100) (SUBCUTANE.), INSULIN DEGLUDEC PEN (U-200) (SUBCUTANE.), INSULIN GLARGINE VIAL (SUBCUTANE.), INSULIN GLARGINE SOLOSTAR PEN (SUBCUTANE.), INSULIN GLARGINE-YFGN VIAL (SUBCUTANE.), INSULIN GLARGINE-YFGN PEN (SUBCUTANE.), SEMGLEE (YFGN) PEN (SUBCUTANE.), and SEMGLEE (YFGN) VIAL (SUBCUTANE.) to be added to the PDL as NONPREFERRED
 - SEMGLEE VIAL to be removed from the PDL
- The committee discussed the Immunomodulators, Atopic Dermatitis therapeutic class and recommended the following to the department by a unanimous vote:
 - ADBRY (SUBCUTANEOUS) and OPZELURA (TOPICAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Immunosuppressives, Oral therapeutic class and recommended the following to the department by a unanimous vote:
 - REZUROCK (ORAL) and TAVNEOS (ORAL) to be added to the PDL as NONPREFERRED
- The committee discussed the Intranasal Rhinitis Agents therapeutic class and recommended the following to the department by a unanimous vote:
 - RYALTRIS (NASAL) to be added to the PDL as NONPREFERRED
- The committee discussed the Lipotropics, Other therapeutic class and recommended the following to the department by a unanimous vote:
 - ICOSAPENT ETHYL (ORAL) and LEQVIO (SUBCUTANEOUS) to be added to the PDL as NONPREFERRED
- The committee discussed the Macrolides/Ketolides therapeutic class and recommended the following to the department by a unanimous vote:
 - ERYTHROMYCIN BASE TABLET DR (ORAL) to be added to the PDL as NONPREFERRED
 - PCE (ORAL) and ZMAX (ORAL) to be removed from the PDL
- The committee discussed the Multiple Sclerosis Agents therapeutic class and recommended the following to the department by a unanimous vote:
 - DIMETHYL FUMARATE DR (ORAL) to be added to the PDL as PREFERRED
 - DIMETHYL FUMARATE DR STARTER PACK (ORAL) and FINGOLIMOD (ORAL) to be added to the PDL as NONPREFERRED.
 - DHS will manage the utilization of Gilenya and its generic, fingolimod based on the lowest net cost.
- The committee discussed the NSAIDS therapeutic class and recommended the following to the department by a unanimous vote:
 - FLECTOR (TOPICAL) to be moved to the PDL as NONPREFERRED
 - IBUPROFEN/FAMOTIDINE TABLET (ORAL), KETOPROFEN ER (ORAL), KETOROLAC (SPRIX) (NASAL), LICART PATCH (TRANSDERMAL), MELOXICAM CAPSULE (ORAL), MECLOFENAMATE (ORAL), NALFON (ORAL), NAPRELAN (ORAL), NAPROXEN CR (ORAL), NAPROXEN/ESOMEPRAZOLE (ORAL), RELAFEN DS (ORAL), SPRIX (NASAL) and VIVLODEX (ORAL) to be added to the PDL as NONPREFERRED
- The committee discussed the Ophthalmic Antibiotics therapeutic class and recommended the following to the department by a unanimous vote:
 - BACITRACIN (OPHTHALMIC), NATACYN (OPHTHALMIC) and SULFACETAMIDE OINTMENT (OPHTHALMIC) to be added to the PDL as NONPREFERRED
- The committee discussed the Ophthalmics, Anti-Inflammatories therapeutic class and recommended the following to the department by a unanimous vote:
 - DEXTENZA (INTRAOCULAR), DIFLUPREDNATE (OPHTHALMIC), DIFLUPREDNATE (AG) (OPHTHALMIC), DUREZOL (OPHTHALMIC), ILEVRO (OPHTHALMIC), LOTEPREDNOL GEL (AG) (OPHTHALMIC) and LOTEPREDNOL GEL (OPHTHALMIC) to be added to the PDL as NONPREFERRED

- The committee discussed the Ophthalmics, Glaucoma Agents therapeutic class and recommended the following to the department by a unanimous vote:
 - BETIMOL (OPHTHALMIC), BRIMONIDINE TARTRATE/TIMOLOL DROPS (OPHTHALMIC) and TIMOLOL (TIMOPTIC OCCUDOSE) (OPHTHALMIC) to be added to the PDL as NONPREFERRED
- The committee discussed the Opiate Dependence Treatments therapeutic class and recommended the following to the department by a unanimous vote:
 - NALOXONE SPRAY (NASAL) and ZIMHI (INJECTION) to be added to the PDL as NONPREFERRED
- The committee discussed the Otic Antibiotics therapeutic class and recommended the following to the department by a unanimous vote:
 - CIPRODEX (OTIC) to be added to the PDL as PREFERRED (was previously removed in error)
 - CORTISPORIN-TC (OTIC) to be added to the PDL as NONPREFERRED
 - OTIPRIO (OTIC) to be removed from the PDL
- The committee discussed the PAH Agents, Oral and Inhaled therapeutic class and recommended the following to the department by a unanimous vote:
 - TYVASO DPI (INHALATION) to be added to the PDL as NONPREFERRED
- The committee discussed the Sedative Hypnotics therapeutic class and recommended the following to the department by a unanimous vote:
 - QUVIVIQ (ORAL) to be added to the PDL as NONPREFERRED
- The committee discussed the Smoking Cessation therapeutic class and recommended the following to the department by a majority vote:
 - VARENICLINE TARTRATE (ORAL) to be added to the PDL as PREFERRED
- The committee discussed the Stimulants and Related Agents therapeutic class and recommended the following to the department by a unanimous vote:
 - That this item be tabled at this meeting pending further review by DHS
- The committee discussed the Ulcerative Colitis Agents therapeutic class and recommended the following to the department by a unanimous:
 - MESALAMINE ER (PENTASA) (ORAL) to be added to the PDL as NONPREFERRED
- The committee discussed the Weight Management Agents therapeutic class and recommended the following to the department by a unanimous vote:
 - CONTRAVE (ORAL), SAXENDA (SUBCUTANEOUS) and WEGOVY (SUBCUTANEOUS) to be added to the PDL as PREFERRED
 - ORLISTAT (ORAL) and XENICAL (ORAL) to be added to the PDL as NONPREFERRED

Existing Drugs and Specialty Drugs for Continued Prior Authorization (PA)

- The committee discussed the proposed updated Anti-Obesity Medications PA Criteria and passed the policy by a unanimous vote.
- The committee discussed the proposed updated Hepatitis C PA Criteria and passed the policy by a unanimous vote.

Adjournment

- The meeting was adjourned at approximately 8:48 p.m. Central Time.